Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 9;18(1):164.
doi: 10.3390/s18010164.

Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications

Affiliations
Review

Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications

Loubna El Harrad et al. Sensors (Basel). .

Abstract

A large number of enzyme inhibitors are used as drugs to treat several diseases such as gout, diabetes, AIDS, depression, Parkinson's and Alzheimer's diseases. Electrochemical biosensors based on enzyme inhibition are useful devices for an easy, fast and environment friendly monitoring of inhibitors like drugs. In the last decades, electrochemical biosensors have shown great potentials in the detection of different drugs like neostigmine, ketoconazole, donepezil, allopurinol and many others. They attracted increasing attention due to the advantage of being high sensitive and accurate analytical tools, able to reach low detection limits and the possibility to be performed on real samples. This review will spotlight the research conducted in the past 10 years (2007-2017) on inhibition based enzymatic electrochemical biosensors for the analysis of different drugs. New assays based on novel bio-devices will be debated. Moreover, the exploration of the recent graphical approach in diagnosis of reversible and irreversible inhibition mechanism will be discussed. The accurate and the fast diagnosis of inhibition type will help researchers in further drug design improvements and the identification of new molecules that will serve as new enzyme targets.

Keywords: diagnosis of inhibition; disease; drug; electrochemical biosensors; enzyme inhibition.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Relationship between in silico prediction and new analytical tools and their importance in drug therapy as preliminary assays before proceeding to in vivo tests.
Scheme 1
Scheme 1
Kinetics of non-inhibitive enzymatic reaction (A), irreversible enzyme inhibition (B) and reversible enzyme inhibition (C).
Figure 2
Figure 2
Degree of inhibition determination using enzyme-based electrochemical biosensor.
Figure 3
Figure 3
Effect of incubation time (A) and enzyme concentration (B) on I50 in the case of irreversible inhibition.
Figure 4
Figure 4
Variation of I50 in function of time in case of irreversible inhibition. The curve was plotted using the equation of I50=0.69×Ki((Kinac×t)+0.69) and the following parameters were used: Ki=0.84 µM, Kinac=0.25 min1.
Figure 5
Figure 5
Effect of concentration of substrate on I50 in case of reversible inhibition (curve a) competitive, (curve b) non-competitive and (curve c) uncompetitive.
Figure 6
Figure 6
Schematic presentation of different biosensors based on numerous bio-recognition elements.

References

    1. Aigner M., Preissegger P., Kalcher K., Mehmeti E., Macheroux P., Edmondson D., Ortner A. Biosensor for the characterisation of hMAO B inhibitors and the quantification of selegiline. Talanta. 2017;174:696–702. doi: 10.1016/j.talanta.2017.06.079. - DOI - PubMed
    1. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed. Pap. 2011;155:219–223. doi: 10.5507/bp.2011.036. - DOI - PubMed
    1. Ignaszak A., Hendricks N., Waryo T., Songa E., Jahed N., Ngece R., Al-Ahmed A., Kgarebe B., Baker P., Iwuoha E.I. Novel therapeutic biosensor for indinavir—A protease inhibitor antiretroviral drug. J. Pharm. Biomed. Anal. 2009;49:498–501. doi: 10.1016/j.jpba.2008.10.025. - DOI - PubMed
    1. Overall C.M., Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer. 2006;6:227–239. doi: 10.1038/nrc1821. - DOI - PubMed
    1. Barry M., Feely J. Enzyme induction and inhibition. Pharmacol. Ther. 1990;48:71–94. doi: 10.1016/0163-7258(90)90019-X. - DOI - PubMed

Substances

LinkOut - more resources